EPISODE · Mar 28, 2026 · 13 MIN
Episode 31: Certificate of Analysis
from Policy, Decoded · host The Homegrown Consulting Group
🎙️ Powered by THC Group, Policy, Decoded is the Sunday briefing that steps back from the churn and unpacks one consequential policy story shaping cannabis, hemp, alcohol, and regulated markets.This week, we examine the structural failure underneath the legal cannabis market's most important promise.Everyone agrees that testing matters. Legislators say it. Regulators build their frameworks around it. Operators absorb the cost. Voters feel reassured by it. That consensus has held from the earliest days of legalization through every state that followed. It has also, on its own, not been nearly enough.Since January 2023, at least eleven testing laboratories have faced formal enforcement action across six states. In Michigan, a lab that tested 60 percent of the state's cannabis was permanently shut down after technicians classified visible mold as mite feces. In Massachusetts, a lab reported yeast and mold failure rates ninety times below the statewide average. In California, a lab director signed a certificate of analysis clearing a product that contained a banned pesticide at 600 times the permissible level. In Oregon, seven of the state's eleven accredited labs were cited simultaneously, three for adding kief directly to testing samples.This episode walks through what that record reveals about two distinct structural vulnerabilities in cannabis testing. The first is lab shopping, where operators seek the lab most likely to return favorable results. The second is less discussed and may be more consequential: in most states, operators select their own compliance samples. When sampling is compromised, even excellent laboratory work cannot protect patients.We explore why potency inflation gets the headlines but contamination failures carry the real clinical risk, how testing costs and affordability gaps push vulnerable patients toward the unregulated market, why the emerging state reference lab movement risks replicating fragmentation rather than building shared standards, and what the repeal campaigns gathering strength in Massachusetts and elsewhere are doing with the testing record.The legal cannabis market built its entrance on a safety promise. The testing system underneath that promise was designed with structural flaws that most states have not corrected. The opposition does not need to manufacture a crisis. The testing record is assembling one.The question is whether the industry and its regulators fix it before someone else uses the evidence to take the whole project apart.🔗 Read the full Sunday editorialSubscribe to the Sunday briefing This podcast may include content written or produced with the support of AI tools under human direction and editorial oversight.
What this episode covers
🎙️ Powered by THC Group, Policy, Decoded is the Sunday briefing that steps back from the churn and unpacks one consequential policy story shaping cannabis, hemp, alcohol, and regulated markets.This week, we examine the structural failure underneath the legal cannabis market's most important promise.Everyone agrees that testing matters. Legislators say it. Regulators build their frameworks around it. Operators absorb the cost. Voters feel reassured by it. That consensus has held from the earliest days of legalization through every state that followed. It has also, on its own, not been nearly enough.Since January 2023, at least eleven testing laboratories have faced formal enforcement action across six states. In Michigan, a lab that tested 60 percent of the state's cannabis was permanently shut down after technicians classified visible mold as mite feces. In Massachusetts, a lab reported yeast and mold failure rates ninety times below the statewide average. In California, a lab director signed a certificate of analysis clearing a product that contained a banned pesticide at 600 times the permissible level. In Oregon, seven of the state's eleven accredited labs were cited simultaneously, three for adding kief directly to testing samples.This episode walks through what that record reveals about two distinct structural vulnerabilities in cannabis testing. The first is lab shopping, where operators seek the lab most likely to return favorable results. The second is less discussed and may be more consequential: in most states, operators select their own compliance samples. When sampling is compromised, even excellent laboratory work cannot protect patients.We explore why potency inflation gets the headlines but contamination failures carry the real clinical risk, how testing costs and affordability gaps push vulnerable patients toward the unregulated market, why the emerging state reference lab movement risks replicating fragmentation rather than building shared standards, and what the repeal campaigns gathering strength in Massachusetts and elsewhere are doing with the testing record.The legal cannabis market built its entrance on a safety promise. The testing system underneath that promise was designed with structural flaws that most states have not corrected. The opposition does not need to manufacture a crisis. The testing record is assembling one.The question is whether the industry and its regulators fix it before someone else uses the evidence to take the whole project apart.🔗 Read the full Sunday editorialSubscribe to the Sunday briefing This podcast may include content written or produced with the support of AI tools under human direction and editorial oversight.
NOW PLAYING
Episode 31: Certificate of Analysis
No transcript for this episode yet
Similar Episodes
No similar episodes found.